Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PRIMACOR (milrinone) is an inotropic agent administered by injection for acute decompensated heart failure and cardiogenic shock. As a phosphodiesterase-3 inhibitor, it increases cardiac contractility and produces vasodilation. The drug is indicated for short-term IV therapy in patients requiring inotropic support.
Product is in late-stage lifecycle with moderate competitive pressure (30%), signaling potential team rightsizing and a focus on cost management rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PRIMACOR offers limited new career growth opportunities given its mature, approaching-LOE status and lack of linked job openings. Roles available tend to be in steady-state hospital management, compliance, and cost optimization rather than launch or growth-phase activities.
Worked on PRIMACOR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.